HCA
APLS

Harbour Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Harbour Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,487
Closed -$477K – 258
2022
Q4 		$477K Buy
9,487
+2,717
+40% +$144K 0.16% 132
2022
Q3 		$392K Buy
+6,770
New +$401K 0.14% 145

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbour Capital Advisors's APLS Position: Q1 2023 in Review

Harbour Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q1 2023, closing a stake of 9,487 shares — an estimated $477K sold.

Harbour Capital Advisors first reported a position in APLS in Q3 2022 and held it in 2 quarters. The position peaked at $477K in Q4 2022. 281 funds tracked by Wall St. Rank hold APLS as of Q1 2023.

  • Harbour Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Harbour Capital Advisors sold 9,487 Apellis Pharmaceuticals shares in Q1 2023, an estimated $477K.
  • Harbour Capital Advisors first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Harbour Capital Advisors's Apellis Pharmaceuticals position peaked at $477K in Q4 2022.
  • 281 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2023.

Based on Harbour Capital Advisors's 13F filing for Q1 2023, filed 19 Apr 2023.